Cytovance Biologics Capacity Update April 2025: Large Molecule Development

Cytovance will make another appearance at an Outsource Pharma Capacity Update. Stijn Cattaert, Director of Business Development, is excited to share the company’s microbial and mammalian capabilities as well as their available capacity. Centrally located in the United States, with a decades-long history in biologics development and manufacturing,

Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike. List of capabilities presented: Biologics Development and Manufacturing for Microbial and Mammalian-expressed proteins including:

• Biosimilars
• Cytokines
• Enzymes/Hormones
• Fusion Proteins
• Bispecific, Fragment, and Monoclonal Antibodies
• Recombinant Protein
• Vaccines
• And More